摘要
目的 观察冠心病合并房颤抗凝与双联抗血小板治疗效果,并予以比较.方法 选取本院2015年10月至2017年10月收治的200例冠心病合并房颤患者作为研究对象,将所选患者随机分为观察组100例,使用硫酸氢氯吡格雷联合阿司匹林双联抗血小板治疗,另外100例患者作为对照组,使用华法林钠进行抗凝治疗,比较两组患者治疗效果.结果 通观察组患者治疗过程中出现出血情况、次要终点事件以及主要终点事件的发生率均显著低于对照组患者;且观察组患者CHADS2法以及HAS-BLED法评分分别为(6.71 ±0.34)分、(4.10±0.25)分高于对照组患者CHADS2法以及HAS-BLED法评分(7.01±0.49)分、(5.62±0.49)分.差异具有统计学意义.结论 对于冠心病合并房颤患者使用双联抗血小板治疗,有助于缓解患者临床症状,提升临床治疗效果,降低不良反应发生率.
Objective To observe the effect of anticoagulant and double antiplatelet therapy of coronary heart disease complicated with atrial fibrillation and compare it.Methods 200 patients with coronary heart disease complicated with atrial fibrillation were selected from October 2015 to October 2017 as the research object,the selected patients were randomly divided into observation Group 100 cases,using clopidogrel sulfate combined with aspirin double antiplatelet therapy,another 100 patients as control group,Anticoagulant therapy was performed with sodium warfarin to compare the therapeutic effects of the two groups.Results The incidence of hemorrhage,secondary endpoint events and primary endpoint events were significantly lower in the treatment of patients in the observation group than in the control group,and the scores of CHADS2 method and Has-bled method were(6.71±0.34),respectively,(4.10±0.25).The CHADS2 method was higher than that of the control group,and the score(7.01±0.49)and(5.62±0.49)of the Has-bled method were divided.The difference is statistically significant.Conclusion the use of double antiplatelet therapy in patients with coronary heart disease complicated with atrial fibrillation is helpful to relieve the clinical symptoms,improve the clinical treatment effect and reduce the incidence of adverse reactions.
作者
晋章明
余志杰
JIN Zhang-ming;YU Zhi-jie(Department of Cardiology,Zhenan County Hospital,Shangluo City,Shaanxi Pmvince,Shangluo,711500,China;Matemal and Child Health Hospital,Zhen'an County,Shangluo City)
出处
《血栓与止血学》
2019年第1期60-62,共3页
Chinese Journal of Thrombosis and Hemostasis
关键词
冠心病
房颤
抗凝
双联抗血小板治疗
Coronary heart disease
Atrial fibrillation
Anticoagulant
Double antiplatelet therapy
